Kurs Zeit an
Hier der Text:
Bayer expects dynamic growth with higher profitability
in the coming years and is accelerating its transformation
Crop Science: Clear innovation leader in its industry – expected sales and earnings
growth above market
Pharmaceuticals: Further growth planned through 2023, new products expected to
largely offset the effect of patent expirations – position in cell and gene therapy to be
expanded
Consumer Health: Moved from industry underperformer to outperformer – further sales
and earnings improvements planned
Core earnings per share anticipated to increase to 7.00 to 7.50 euros by 2024
Further operational improvements to raise free cash flow to 5 billion euros by 2024
Bayer in an excellent position to benefit from the biorevolution in health and nutrition
Hier der Text:
Bayer expects dynamic growth with higher profitability
in the coming years and is accelerating its transformation
Crop Science: Clear innovation leader in its industry – expected sales and earnings
growth above market
Pharmaceuticals: Further growth planned through 2023, new products expected to
largely offset the effect of patent expirations – position in cell and gene therapy to be
expanded
Consumer Health: Moved from industry underperformer to outperformer – further sales
and earnings improvements planned
Core earnings per share anticipated to increase to 7.00 to 7.50 euros by 2024
Further operational improvements to raise free cash flow to 5 billion euros by 2024
Bayer in an excellent position to benefit from the biorevolution in health and nutrition